Lord, Abbett & Co
LENZ

Lord, Abbett & Co’s LENZ Therapeutics LENZ Stock Holding History

Lord, Abbett & Co’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-114,612
Closed -$5.34M – 610
2025
Q3 		$5.34M Sell
114,612
-17,118
-13% -$629K 0.02% 456
2025
Q2 		$3.86M Buy
131,730
+82,108
+165% +$2.23M 0.01% 483
2025
Q1 		$1.28M Buy
+49,622
New +$1.22M ﹤0.01% 522

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Lord, Abbett & Co's LENZ Position: Q4 2025 in Review

Lord, Abbett & Co sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 114,612 shares — an estimated $5.34M sold.

Lord, Abbett & Co first reported a position in LENZ in Q1 2025 and held it in 3 quarters. The position peaked at $5.34M in Q3 2025. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

  • Lord, Abbett & Co reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 114,612 LENZ Therapeutics shares in Q4 2025, an estimated $5.34M.
  • Lord, Abbett & Co first reported a position in LENZ Therapeutics in Q1 2025 and held it in 3 quarters.
  • Lord, Abbett & Co's LENZ Therapeutics position peaked at $5.34M in Q3 2025.
  • 160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on Lord, Abbett & Co's 13F filing for Q4 2025, filed 13 Feb 2026.